BEI
DNA icon

Benjamin Edwards Inc’s Ginkgo Bioworks DNA Stock Holding History

Benjamin Edwards Inc’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-43
Closed -$1K – 1112
2024
Q2 		$1K Sell
43
-187
-81% -$5.58K ﹤0.01% 678
2024
Q1 		$11K Buy
230
+58
+34% +$3K ﹤0.01% 635
2023
Q4 		$12K Sell
172
-62
-26% -$3.8K ﹤0.01% 575
2023
Q3 		$17K Buy
234
+42
+22% +$3.36K ﹤0.01% 539
2023
Q2 		$14K Buy
192
+44
+30% +$2.6K ﹤0.01% 548
2023
Q1 		$8K Buy
148
+38
+35% +$2.41K ﹤0.01% 594
2022
Q4 		$7K Buy
110
+31
+39% +$2.85K ﹤0.01% 613
2022
Q3 		$10K Sell
79
-1
-1% -$119 ﹤0.01% 558
2022
Q2 		$8K Buy
80
+28
+54% +$3.42K ﹤0.01% 598
2022
Q1 		$8K Buy
+52
New +$10.1K ﹤0.01% 619

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Benjamin Edwards Inc's DNA Position: Q3 2024 in Review

Benjamin Edwards Inc sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 43 shares — an estimated $1K sold.

Benjamin Edwards Inc first reported a position in DNA in Q1 2022 and held it in 10 quarters. The position peaked at $17K in Q3 2023. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Benjamin Edwards Inc reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Benjamin Edwards Inc sold 43 Ginkgo Bioworks shares in Q3 2024, an estimated $1K.
  • Benjamin Edwards Inc first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 10 quarters.
  • Benjamin Edwards Inc's Ginkgo Bioworks position peaked at $17K in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Benjamin Edwards Inc's 13F filing for Q3 2024, filed 14 Nov 2024.